Portola Receives FDA Approval For Bevyxxa

The FDA has approved Portola Pharmaceuticals Inc PTLA 1.16%’s BevyxXa, a blood-thinner for acutely ill patients not undergoing surgery. BevyxXa is the first oral drug of its kind to be approved to help prevent deep vein thrombosis and pulmonary embolisms.